Loading the company…
Loading the company…
㈜동광제약
English name as filed with DART, Korea’s corporate disclosure system · Correct the English name ›
Last updated 2026-11-02 · Korean page ›
Verification level — how far we have checked
L0 · Public records — NPS workforce · filed financials · patents — public data
A company based in Seoul, founded in 2014. Industry: Bio & Pharma. Revenue for 2025 was ₩242.4bn. It has 522 employees enrolled in the National Pension Service (as of Aug 2026). It is externally audited; the latest audit opinion is “Unqualified”.
Loading…
Latest filing 2024-11-28 · latest registration 2023-06-20 · newest first
본 발명은 N-니트로소 보노프라잔이 억제된 보노프라잔 또는 이의 약학적으로 허용가능한 염을 포함하는 약제학적 조성물을 개시한다.
본 발명은 엠파글리플로진의 무정형 안정화 방법을 개시한다.
본 발명은 메트포르민염산염 내부에 존재하는 불순물인 디메틸아민을 저감하는 방법을 개시한다.
본 발명은 로수바스타틴 또는 이의 약학적으로 허용되는 염 및 페노피브레이트를 함유하는 캡슐 제제를 개시한다.
본 발명은 미라베그론 방출제어 제제에 대한 것으로서, 미라베그론의 방출을 제어하는 하이드로겔 형성 고분자 및 친수성 기제를 포함하며, 보다 안정성이 개선된 제어 방출 제제를 제공할 수 있다.
본 발명은 틸리아닌을 함유하는 곽향(Agastachis Herba) 및 작약(Paeonia lactiflora), 천궁(Ligusticum chuanxiong), 당귀(Angelica gigas), 시호(Bupleurum falcatum), 치자인(Gardenia jasminoides), 목단피(Paeonia suffruticosa), 정향(Eugenia caryophyllata)으로 구성되는 복합 추출물을 포함하는 파킨슨 질환의 예방 또는 치료용 약학적 조성물, 건강기능식품에 대한 것으로, 본 발명의 조성물은 MPTP에 의해 유도된 행동 장애를 개선시키고, 도파민성 뉴런의 손실을 회복시키므로 파킨슨병의 예방, 개선 및 치료에 우수한 효과가 있다.
KIPO KIPRIS · checked 2026-10-15 · newest filings first · right: registration date (filing date if not yet registered) · 6 of 6 · titles and abstracts are in Korean as filed · click a row for details ▾
For now we hold public records only (National Pension Service · DART filings · patents · registers · press). When the company files material in our IR Room, it moves to L1. We do not score or rate companies — we only state how far we have checked.
| KRW bn | 2024 | 2025 |
|---|---|---|
| Revenue | 225.2 | 242.4 |
| Cost of sales | 118.7 | 128.7 |
| Gross profit (loss) | 106.5 | 113.7 |
| Selling, general and administrative expenses | 81.4 | 86.2 |
| Operating income (loss) | 25.0 | 27.6 |
| Non-operating income | 2.2 | 1.9 |
| Other gains | 0.9 | 0.8 |
| Finance income | 1.0 | 1.0 |
| Other | 0.3 | 0.1 |
| Non-operating expenses | 1.8 | 1.2 |
| Other losses | 0.1 | 0.0 |
| Finance costs | 1.6 | 1.0 |
| Other | 0.1 | 0.2 |
| Profit (loss) before tax | 25.4 | 28.2 |
| Income tax expense | 4.5 | 5.3 |
| Net income (loss) | 20.9 | 22.9 |
Revenue ₩242.4bn, up 7.7% YoY.
Operating margin 11.4% (prior 11.1%).
Net income ₩22.9bn.
Need more than is shown here? Ask for more information — full review report · valuation · executive teaser · IM · competitor analysis · due diligence. Tell us what you need and we will reply by email with scope, cost and timing.
Is this your company?
If anything here is wrong, tell us — we check it against the original and correct it. You do not need to join. If you would like your financials verified and this page completed, that is a separate process.
Headlines and links to public articles only · not checked by us (original ↗) · articles are in Korean — English headlines are our translation; where none is shown, “Read in English ›” opens a machine translation · “Broker view” is a forecast, not reported results · checked 2026-11-05